LOBE — Lobe Sciences Income Statement
0.000.00%
Last trade - 00:00- CA$13.47m
- CA$8.95m
Annual income statement for Lobe Sciences, fiscal year end - August 31st, CAD millions except per share, conversion factor applied.
C2021 August 31st | 2022 August 31st | 2023 August 31st | 2024 August 31st | 2025 August 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0.841 | 0.136 | 0 |
| Cost of Revenue | |||||
| Gross Profit | — | — | 0.817 | 0.134 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 16.3 | 4.12 | 5.21 | 4.29 | 3.87 |
| Operating Profit | -16.3 | -4.12 | -4.37 | -4.16 | -3.87 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -23.8 | -12.3 | -4.5 | -4.39 | -4.86 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -22.8 | -12.3 | -4.71 | -4.42 | -4.86 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -9.66 | -12.3 | -4.71 | -4.42 | -4.43 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -9.66 | -12.3 | -4.71 | -4.42 | -4.43 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.504 | -0.324 | -0.039 | -0.025 | -0.034 |